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Introduction: The molecular determinants of breast cancer resistance to first-line anthracycline-containing
chemotherapy are unknown.
Methods: We examined the response to doxorubicin of organotypic cultures of primary human breast tumors
ex vivo with respect to cell proliferation, DNA damage and modulation of apoptosis. Samples were analyzed for
genome-wide modulation of cell death pathways, differential activation of p53, and the role of survivin family
molecules in drug resistance. Rational drug combination regimens were explored by high-throughput screening,
and validated in model breast cancer cell types.
Results: Doxorubicin treatment segregated organotypic human breast tumors into distinct Responder or Non
Responder groups, characterized by differential proliferative index, stabilization of p53, and induction of apoptosis.
Conversely, tumor histotype, hormone receptor or human epidermal growth factor receptor-2 (HER2)
status did not influence chemotherapy sensitivity. Global analysis of cell death pathways identified survivin and
its alternatively spliced form, survivin-ΔEx3 as uniquely overexpressed in Non Responder breast tumors. Forced
expression of survivin-ΔEx3 preserved cell viability and prevented doxorubicin-induced apoptosis in breast
cancer cell types. High-throughput pharmacologic targeting of survivin family proteins with a small-molecule
survivin suppressant currently in the clinic (YM155) selectively potentiated the effect of doxorubicin, but not
other chemotherapeutics in breast cancer cell types, and induced tumor cell apoptosis.
Conclusions: Survivin family proteins are novel effectors of doxorubicin resistance in chemotherapy-naive breast
cancer. The incorporation of survivin antagonist(s) in anthracycline-containing regimens may have improved
clinical activity in these patients.Introduction
Despite considerable progress in the molecular charac-
terization [1], and treatment [2] of breast cancer, drug-
resistant disease remains a common occurrence, often
heralding high morbidity and mortality due to metastatic
progression. The molecular underpinnings of treatment-
resistant breast cancer, which includes insensitivity to anti-
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unless otherwise stated.growth factor receptor-2 (HER2) inhibitors [4], have been
intensely investigated, and linked to aberrant receptor tyro-
sine kinase signaling [5], enhanced drug efflux mechanisms
[6], and defective immune recognition [7]. Although several
strategies have been examined to restore treatment sensi-
tivity in these settings [8,9], resistance to the most com-
mon, first-line anthracycline-containing chemotherapy
[10] continues to represent a significant challenge [11],
with limited, if any, ‘actionable’ molecular targets to restore
drug sensitivity.
In this context, resistance to apoptosis, or programmed
cell death, is a common occurrence of treatment-resistant
malignancies [12], involving deregulated expression of
cell death modulators of the Bcl-2 [13], or inhibitor ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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In chemotherapy-resistant breast cancer, these pathways
further compound other aberrant mechanisms of cell sur-
vival, including loss of the PTEN tumor suppressor gene
[16], reactivation of phosphatidylinositol 3-kinase (PI3K)/
mammalian target of rapamycin (mTOR) signaling
[17], expansion of cancer-initiating, progenitor-like cells
[18], and increased production of vascular endothelial
cell growth factor (VEGF) [19]. Although many of these
pathways contain ‘actionable’ molecular targets, a key
challenge in dissecting their role in drug resistance is the
paucity of reliable disease model(s) that recapitulate the
complexity of the human disease, while preserving the in-
tegrity of the tumor microenvironment, as a recognized
disease driver in breast cancer [20]. To overcome this bar-
rier, short-term ex vivo cultures of organotypic primary
human tumors may provide a flexible translational plat-
form, suitable to evaluate the impact of deregulated signal-
ing pathways [21], and molecular therapies [22], under
conditions that preserve tumor architecture [20].
In this study, we used fresh organotypic tissue cultures
from treatment-naïve human breast tumors to explore
the molecular requirements of anthracycline resistance
[10]. We identified a discrete subgroup of doxorubicin-
insensitive, that is Non Responder tumors, characterized
by high proliferative index, impaired p53 responses and
resistance to apoptosis. In turn, molecular analyses dem-
onstrated that aberrant overexpression of survivin family
proteins [15] is required to maintain the Non Responder
phenotype, opening fresh opportunities for rational com-
bination regimens to restore anthracycline sensitivity in
these patients.
Methods
Patient cohort
Primary human breast tumors were obtained from 33
patients who underwent surgery for therapeutic purposes
at San Paolo Hospital (Milan, Italy). The clinicopathologic
and molecular characteristics of the patients analyzed in
this study are presented in Table 1. Patients who received
neoadjuvant chemotherapy and/or radiotherapy were ex-
cluded from the study. Informed consent was obtained
from all patients and the study was approved by the Insti-
tutional Review Board of the San Paolo Hospital.
Tissue slice preparation
Tissue processing was performed within 20 minutes
after surgical resection. Tissue slices (400 μm thick)
were obtained through serial cutting of the individual
samples using a Vibratome VT1200 (Leica Microsystems,
Milan, Italy), as described previously [22]. For all speci-
mens a tissue slice was collected at baseline time (T0) and
at 24 h intervals for up to 72 h. At each time point, the
individual tissues cultures were harvested, formalin-fixedand paraffin-embedded (FFPE) for morphological and im-
munohistochemical analysis. For 29 samples, tissue was
available for the preparation of a second T0 slice that was
snap-frozen and utilized for molecular studies. A patholo-
gist (SB) examined the tissue cultures to verify the pres-
ence of tumor cells.
Organotypic tissue cultures and treatment
Tissue slices were cultured as described [22]. For treat-
ment, doxorubicin (10 μM, Sigma-Aldrich, St. Louis,
MO, USA) or vehicle (1 μl phosphate-buffered saline
(PBS), Gibco Invitrogen, Life Technologies, Carlsbad,
CA, USA) was added to the culture medium, and
replenished at the same concentration every 24 h.
Immunohistochemical analysis
All samples were analyzed for morphologic integrity and
presence of breast cancer cells by hematoxylin and eosin
(H&E) staining. Immunohistochemical scores in tissue
cultures and T0 samples were determined in the epithelial
tumor cells compartments. Immunostaining was perfor-
med for Ki-67 (MIB1, 1:100, Dako, Milan, Italy), estrogen
receptor (ER, 1D5, 1:200, Dako), and progesterone recep-
tor (PR, PGR-636, 1:100, Dako) on all samples. Tumor
cells immunoreactivity for p53 (Ab5-DO-7, 1:1000, LabVi-
sion/NeoMarkers, Fremont, CA, USA), p21Waf1 (CP-74,
1:1000, Sigma-Aldrich) and MDM2 (Ab1 IF2, 1:100,
Oncogene Science, Wilex Inc., Cambridge, MA, USA)
could be assessed on 31 FFPE samples. Analysis of cleaved
caspase-3 (Asp175, 5A1E, 1:500, Cell Signaling Technology,
Danvers, MA, USA) was carried out on 30 samples. Bind-
ing of the individual primary antibody was detected with a
secondary antibody of appropriate specificity, and visualized
by 4′,6-diamidino-2-phenylindole (DAB) followed by coun-
terstaining with hematoxylin. Negative controls were
prepared in the absence of primary antibody and included
in each reaction. Three investigators (AF, VV and SB)
independently examined and scored all slides. When
discrepancies occurred, the cases were reviewed jointly
until a consensus was reached. For quantification of prolif-
erative activity, a Ki-67 score was determined at diagnosis
as the percentage of positive tumor cells [23]. The data
were correlated to the individual responses to doxorubicin
in the organotypic cultures. A Ki-67 score in organotypic
cultures of breast tumors was calculated as the percentage
of positive cells divided by the entire tumor cell popu-
lation present in the sample. A two-score system for per-
centage of positive cells and intensity of staining was used
to quantify the reactivity for p53, MDM2, p21waf1 and
cleaved caspase-3. The intensity of staining was expressed
in a scale of 0 (absent staining) to 3 (strong staining). A
Ki-67/cleaved caspase-3 ratio was expressed as growth
index (GI) [24]. Data for each time point were normalized
to the samples at baseline (T0). Representative images
Table 1 Clinicopathological and molecular characteristics of breast cancers analyzed (n = 33)a
Case Histotypeb T N Gc ER PR HER2 statusd Ki-67e p53 Doxo classf
BR1 IDC pT1c N1a G2 70% 70% Neg 10% Wt Responder
BR2 IDC pT2 pNx G2 90% 70% Neg 15% R280G Responder
BR3 IDC pT3 N1a G2 80% Neg Neg 20% Wt Non Responder
BR4 IDC pT1c N0 G2 80% 10% Pos 10% Wt Non Responder
BR5 IDC pT2 N3a G3 80% 90% Neg 20% Wt Non Responder
BR6 PC pT2 N2a G3 90% 5% Neg 10% Wt Responder
BR7 DLC pT3 N1 G3 90% 5% Neg 30% Wt Responder
BR8 IDC pT1c N1a G3 80% 70% Neg 25% Wt Responder
BR9 IDC pT1c N0 G2 90% 70% Neg 20% Wt Responder
BR10 IDC pT2 Nx G2 90% 95% Neg 15% Wt Responder
BR11 PC pT2 N0 G1 95% 95% Neg 10% Wt Responder
BR12 IDC pT1c N0 G3 95% 60% Neg 40% Wt Non Responder
BR13 IDC pT1c N0 G2 90% 85% Neg 15% Wt Non Responder
BR14 ILC pT3 N3a G3 25% 40% Pos 20% Wt Non Responder
BR15 IDC pT2 N0 G3 95% 20% Neg 10% Wt Responder
BR16 IDC pT1c N0 G2 95% Neg Neg 5% Wt Non Responder
BR17 IDC pT1c N0 G2 95% 95% Neg 20% Wt Non Responder
BR18 IDC pT3 N3 G3 Neg Neg Neg 45% Wt Responder
BR19 IDC pT2 N2 G3 90% 60% Pos 90% Wt Non Responder
BR20 IDC pT2 N3a G3 90% 2% Pos 10% Wt Responder
BR21 IDC pT2 Nx G3 90% 80% Neg 30% Wt Non Responder
BR22 IDC pT1c N0 G1 90% 90% Neg 5% Wt Responder
BR23 IDC pT1c Nx G2 90% 40% Neg 20% Wt Responder
BR24 IDC pT1c Nx G2 95% 95% Neg 5% Wt Responder
BR25 IDC pT2 N2a G1 90% 75% Neg 5% K132N Responder
BR26 IDC pT2 N1a G2 90% 70% Neg 10% Wt Non Responder
BR27 IDC pT1c N0 G3 90% 90% Neg 20% Wt Non Responder
BR28 IDC pT2 N1a G3 90% 10% Neg 30% Wt Responder
BR29 IDC pT1c N0 G3 90% Neg Neg 25% Wt Responder
BR30 IDC pT1c N1a G1 95% 95% Neg 5% Wt Responder
BR31 IDC pT1c N0 G3 Neg Neg Neg 40% Wt Non Responder
BR32 IDC pT2 N1a G3 95% 70% Neg 25% R248W Non Responder
BR33 IDC pT3 N3a G2 90% 80% Neg 10% Wt Responder
aTumor stage according to TNM staging systems, grade, hormone or HER2 receptor status, tumor proliferation (percentage of Ki-67-positive cells), and p53 gene
mutations are indicated along with our biological class related to the ex vivo doxorubicin treatment. All patients were M0, that is, no distant metastases were
present at diagnosis. bIDC, invasive ductal carcinoma; PC, papillary carcinoma; DLC, ductal and lobular carcinoma; ILC, invasive lobular carcinoma.cG, tumor grade.
dHER2 status was determined according to American Society of Clinical Oncology guidelines (2007). eKi-67 index as determined at diagnosis (approximate to the
nearest 5%). fDoxorubicin class was assigned to breast cancers depending on the decrease of proliferating cells upon ex vivo doxorubicin treatment of at least
50% (Responders) or the maintenance of Ki-67-positive cells similar to control treated cultures (Non Responders).
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tems) and contrast/brightness was adjusted using Photo-
shop (Adobe Systems Inc., San Jose, CA, USA).
p53 mutational analysis
DNA was purified from frozen or FFPE samples at T0
and amplified with specific primers for p53 exons 5 to 9(Table S1 in Additional file 1). Both amplicon strands
were sequenced using the BigDye Terminators chemistry
(Applied Biosystems, Life Technologies, Carlsbad, CA,
USA), and purified using DyeEx 2.0 Spin Kit (Qiagen,
Manassas, VA, USA). DNA sequences were performed
using a 3130 Genetic Analyzer (Applied Biosystems, Life
Technologies).
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Total RNA was extracted from frozen tissues using
RNeasy Mini Kit (Qiagen) according to the supplier’s
protocol. One μg of total RNA was reverse-transcribed
using High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Life Technologies).Apoptotic gene profiling
Gene expression analysis of apoptotic-related genes was
analyzed in five Responder and five Non Responder
cases of organotypic breast tumors using RNA purified
from T0 samples before culture by custom Microfluidic
Cards technology (Applied Biosystems, Life Technolo-
gies). This platform allows for simultaneous expression
analysis of 92 apoptosis-related genes (Table S2 in Add-
itional file 1) and three reference genes (ACTB, TBP and
HMBS) for target gene relative quantification. Eight hun-
dred ng of cDNA for each sample was loaded in duplicate
per card, analyzed using an ABI Prism 7900HT sequence
detection system, and targets raw data (Ct values) were
converted into relative quantities using GeNorm software
[25]. Relative quantity RQ values were then median-
normalized and log2-transformed for statistical analysis.
All reagents, instruments and software were by Applied
Biosystems, Life Technologies.Real time RT-PCR (qPCR)
Gene expression levels of tumor necrosis factor-alpha
(TNFα), baculoviral IAP repeat- containing 3 (BIRC3),
survivin (BIRC5) isoform 1, survivin-2B (isoform 3), or
survivin-ΔEx3 (isoform 2) were analyzed in duplicate
using gene-specific primers and probes (Table S3 in
Additional file 1) and the ABI Prism 7900HT sequence
detection system. β-2 microglobulin (β2M) was used as
reference gene for target genes relative quantification
using the 2-ΔCt formula.In vitro experiments
Human breast cancer MCF-7, MDA-MB231 and HS578T
cells were obtained from the American Type Culture Col-
lection (ATCC, Manassas, VA, USA) and maintained in
culture in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS) supplemented
with 100 U/ml penicillin/streptomycin and 2 mM L-glu-
tamine at 37°C and 5% CO2, as recommended by the
supplier. MCF-7 cells (2×106/well in a six-well plate) were
transfected with 2 μg of vectors containing survivin-ΔEx3
cDNA or control plasmid [26] in the presence of lipofec-
tamine 2000 (Invitrogen, Life Technologies, Carlsbad, CA,
USA) for 24 h. Transfected cells were treated with 1 μM
doxorubicin or vehicle (PBS) for 24 h, released for
additional 24 h and analyzed for functional experiments.Immunofluorescence
Snap-frozen tissue sections derived from seven organo-
typic breast tumors or MCF-7 cells were fixed in 4% para-
formaldehyde (PFA) (Sigma-Aldrich), and incubated with
a primary antibody to phospho-histone H2AX (pSer139)
(γH2AX, 1:700, Sigma-Aldrich) for 16 h at 22°C. Anti-
rabbit 647 or 548 Alexa Fluor-conjugated was used as a
secondary antibody (Molecular Probes, Invitrogen), and
nuclei were stained with 4′,6-diamidino-2-phenylindole
(DAPI) (Abbott Laboratories, Abbott Park, IL, USA). Slides
were scored by fluorescence microscopy using an AxioIma-
ger Z1 microscope (Carl Zeiss, Göttingen, Germany) and
photographed images were arranged with Photoshop. For
each sample, 100 cells were analyzed and the H2AX
phosphorylation index was calculated as a percentage
of γH2AX-positive cells [26].
Cell viability and TUNEL assays
Cell viability was assessed in MCF-7 cells in the presence of
5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenylte-
trazolium bromide assay (MTT, Sigma-Aldrich) for 4 h at
37°C, and determination of absorbance at 570 nm. Apop-
totic cells were quantified by terminal deoxynucleotidyl
transferase dUTP nick-end labeling (TUNEL) assay using
an ApopTag In Situ Apoptosis Detection Kit (Millipore,
Billerica, MA, USA) following the manufacturer’s protocol.
For combination experiments, MCF-7 or HS578T cells
were incubated with 5 nM of the survivin small-
molecule suppressant YM155 (Selleckchem, Houston,
TX, USA) prepared as stock solutions (10 μM) in
dimethyl sulfoxide (DMSO) in the presence or absence of
doxorubicin (1 to 4 μM, Selleckchem) or vehicle (DMSO).
MDA-MB231 cells were incubated with 10 nM YM155.
After 24 h incubation, cells under the various conditions
tested were analyzed for cell viability by Trypan blue exclu-
sion and light microscopy. Alternatively, treated MCF-7
cells were washed in PBS, pH 7.2, fixed in cold 70% ethanol
overnight at 4°C, stained with propidium iodide (0.2 g/ml),
and analyzed for DNA content by flow cytometry on a
FACSCalibur instrument (Beckman Coulter, Indianapolis,
IN, USA). Cell death was quantified in three independent
experiments by detection of a population with hypodiploid
(sub-G1) DNA content using FlowJo Software (Tree
Star, Inc., Ashland, OR, USA). In other experiments,
drug-treated MCF-7 cells were analyzed by Western blot-
ting with primary antibodies to cleaved caspase-3 (Asp175)
(Cell Signaling), or poly-ADP ribose polymerase (PARP)
(46D11) (Cell Signaling). An antibody to β-actin (Sigma-
Aldrich) was used as control.
Synergy studies
MCF-7 cells (1.7×104/cm2) were treated simultaneously
with YM155 (0.0004 to 0.1 μmol/L) and either doxorubi-
cin, taxol, camptothecin, or etoposide (dose range for each
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tions for 48 h. Cell viability under the various conditions
tested was determined by the addition of resazurin to a
final concentration of 50 μM and incubation for 5 h.
Fluorescence intensity (excitation, 560 nm; emission,
590 nm) was measured on an Envision Xcite Multilabel
Reader (Perkin-Elmer, Waltham, MA, USA), and the frac-
tional growth inhibition was determined by normalizing
assay wells (n = 2) to the aggregated average responses of
positive control (10 μM doxorubicin) and negative control
(0.2% DMSO) treatments (n = 12). Synergy between YM155
and chemotherapeutic agents was determined by Bliss
independence analyses [27]. The Bliss expectation (E)
for a combined response was calculated by the equation:
E = (A + B) - (A × B) where A and B are the fractional
growth inhibitions of drug A and B at a given dose. The
difference between the Bliss expectation and the observed
growth inhibition of the combination of drugs A and B at
the same dose is the ‘Excess over Bliss’. Excess over Bliss
scores = 0 indicates that the combination treatment is
additive (as expected for independent pathway effects);
Excess over Bliss scores >0 indicates activity greater than
additive (synergy); and Excess over Bliss scores <0 indi-
cates the combination is less than additive (antagonism).
Each experiment was independently repeated twice with
comparable results.
Statistical analysis
Data were analyzed using Prism 4.0 (GraphPad Inc, La
Jolla, CA, USA). Differences among sample groups were
analyzed using the unpaired Student’s t test. The associ-
ation between Ki-67 levels and clinicopathological or
molecular parameters in the various patients was evalu-
ated by Fisher’s exact test. The expression profiling of
apoptotic genes in organotypic breast tumors was ana-
lyzed using the web-based BRB-ArrayTools software
[28] and Ingenuity Pathway system (Ingenuity Systems
Inc., Redwood City, CA, USA). Statistical significance
was assumed for a probability value (P) less than 0.05.
Results
Organotypic breast tumor responses to DNA-damaging
agents
We began this study by examining the response of 33
treatment-naïve ex vivo human breast tumors [22] to
anthracycline-containing therapy. Treatment of organo-
typic breast tumors with doxorubicin (10 μM) decreased
cell proliferation at 24-h time intervals, throughout a
72-h culture (Figure 1A). In contrast, administration of
vehicle had no effect on tumor cell proliferation in these
settings (Figure 1A). Doxorubicin treatment did not alter
the hormone receptor status of ex vivo breast tumors,
including estrogen and progesterone receptors (Figure S1A
and B in Additional file 1). Consistent with a predictedinduction of DNA damage, doxorubicin-treated organoty-
pic cultures exhibited high levels of phosphorylated histone
H2AX (γH2AX), a cellular marker of double-strand
DNA breaks (DSB) (Figure 1B), compared to vehicle-
treated cultures or tumors harvested at baseline condi-
tions (Figure 1C). Under these conditions, doxorubicin
treatment identified two discrete subgroups of ex vivo
breast tumors, characterized by radically different prolifer-
ative responses. In 19 out of 33 samples (57%), treatment
with doxorubicin induced a decrease in proliferating cells
over the last time interval (Figure 1D) equal to or greater
than 50% (Ki-67 immunoreactivity range, 0 to 50%), com-
pared to control cultures (Figure 1E). These breast tumors
were designated as Responders in our study. Conversely,
the remaining 14 breast tumors (42%) exhibited no signifi-
cant decrease in proliferative index throughout exposure
to doxorubicin (Figure 1F), quantitatively indistinguishable
to that of vehicle-treated cultures (Ki-67 immunoreactivity
range 70 to 180%; Figure 1G). These doxorubicin-resistant
breast tumors were designated as Non Responders in the
study. Consistent with this working classification, organo-
typic breast tumors in the Responder group exhibited a
lower proliferative index at diagnosis with <15% Ki-67-
positive cells, whereas tumors in the Non Responder
group had higher proliferative index, by Ki-67 staining
(mean levels: 16% versus 26%, respectively, P = 0.04; Fig-
ure 1H). No other significant association was observed
between the different levels of Ki-67 immunoreactivity in
Responder and Non Responder breast tumors and histo-
logic type (P = 0.1), tumor size (P = 0.7), lymph node status
(P = 0.2), hormone receptor expression (ER, P = 0.8; PR,
P = 0.3), or HER2 status (P = 0.2). As expected, Ki-67
immunoreactivity displayed a trend to associate with
tumor grade (P = 0.06).
Differential regulation of apoptosis in organotypic breast
tumors
In addition to decreased cell proliferation, treatment of
organotypic breast tumors with doxorubicin resulted in
increased expression of cleaved, that is active caspase-3,
a marker of terminal activation of apoptosis (Figure 2A).
When stratified according to the Responder versus Non
Responder classification, doxorubicin induced caspase-3
cleavage almost exclusively in the Responder popula-
tion of breast tumors (Figure 2B and C). In contrast,
Non Responder samples had virtually no increase in active
caspase-3 generation after doxorubicin treatment through-
out a 72-h culture (Figure 2B and C). Similarly, Responder
breast tumors exhibited progressive suppression of a GI,
calculated as the ratio between Ki-67 immunoreactivity
and cleaved caspase-3 in response to doxorubicin treat-
ment (24) (Figure 2D). In contrast, Non Responder tumors
continued to exhibit high GI throughout a 72-h doxo-
rubicin treatment (Figure 2D). Despite the extensive
Figure 1 Response of organotypic breast tumors to doxorubicin. (A) Ex vivo cultures of primary human breast tumors (n = 33) were
incubated with 10 μM doxorubicin (Doxo) for the indicated time intervals, and analyzed for Ki-67 expression compared to baseline levels (T0),
by immunohistochemistry. *P = 0.03; **P = 0.009 (unpaired t test). Each circle corresponds to an individual tumor. (B, C) Ex vivo tumor samples
were analyzed for phosphorylation of histone H2AX (γH2AX) by immunofluorescence, with quantification of γH2AX-reactive cells after 48 h (C).
**P = 0.002 (unpaired t test). (D) Responder breast tumors (n = 19) were treated with Doxo or vehicle (Ctrl) and analyzed for changes in cell
proliferation by Ki-67 expression relative to T0 baseline at the indicated time intervals. Original magnification x200. (E) Quantification of Ki-67
expression in Responder breast tumors treated with Doxo or Ctrl for the indicated time intervals. *P = 0.02; **P = 0.0003 (unpaired t test). (F)
Non Responder breast tumors (n = 14) were treated with Ctrl or Doxo, and analyzed for Ki-67 expression relative to T0 as in (D). Original magnification
x200. (G) Quantification of Ki-67 expression in Non Responder breast tumors treated with Doxo or Ctrl for the indicated time intervals. (H) Responders
and Non Responders breast tumors were analyzed for baseline Ki-67 immunoreactivity (% of positive nuclei). *P = 0.04 (Fisher’s exact test). For all
experiments, bars represent mean ± SEM.
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(Figures 1, 2), Responder and Non Responder breast tu-
mors showed comparable reactivity for γH2AX induction
in response to doxorubicin treatment (Figure 2E).As an upstream regulator of apoptosis and cell cycle
arrest in response to DNA damage, we next investigated a
potential differential activation of p53 in organotypic breast
tumors. Doxorubicin treatment resulted in increased
Figure 2 Differential induction of apoptosis in doxorubicin-treated organotypic breast tumors. (A) Breast tumors (n = 33) were incubated
with 10 μM doxorubicin (Doxo) for the indicated time intervals and analyzed for cleaved caspase-3 (Casp3), by immunohistochemistry. (B)
Responder (n = 19) versus Non Responder (n = 14) breast tumors were analyzed for Casp3 expression after 72 h treatment with vehicle (Ctrl) or
Doxo by immunohistochemistry. Original magnification x 400. (C) Quantification of Casp3 immunoreactivity in Non Responder versus Responder
breast tumors at the indicated time intervals after Doxo treatment. #P = 0.04; *P = 0.02. (D) Quantification of growth index (GI) in Responder
versus Non Responder breast tumors at the indicated time intervals after Doxo treatment. *P = 0.02; ***P = 0.0005 (unpaired t test). Each circle
corresponds to an individual tumor. (E) γH2AX-reactive cells were quantified after 48 h treatment with Doxo in Responder or Non Responder
breast tumors by fluorescence microscopy. For all experiments, bars represent mean ± SEM.
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and upregulation of its transcriptional target, p21waf1
(Figure S2B in Additional file 1). In contrast, protein levels
of the p53 regulator, MDM2 were not significantly affec-
ted (Figure S2C in Additional file 1). When analyzed in
the functional tumor subgroups, doxorubicin-induced im-
munoreactivity for p53 (Figure 3A and B) and p21waf1
(Figure 3A and C) almost exclusively segregated with
Responder tumors throughout a 24- to 48-h treat-
ment. In contrast, Non Responder tumors did not exhibit
p53 stabilization (Figure 3A), or upregulation of p21waf1
(Figure 3A and C) after exposure to doxorubicin for thesame time intervals. Although no changes in MDM2
levels were observed in unfractionated organotypic tumors
(Figure S2C in Additional file 1), analysis of tumor sub-
groups revealed a significant increase in MDM2 protein
levels in Responder compared to Non Responder breast
tumors (Figure 3A and D). The differences in p53 pathway
induction in Responder versus Non Responder breast
tumors was independent of p53 gene mutations, as
sequence analysis of p53 exons 5 to 9 revealed comparable
mutation frequencies among Responder and Non
Responder samples (10% and 7%, respectively, P =
0.73; Table 1).
Figure 3 Differential p53 pathway activation in organotypic breast tumors. (A) Immunohistochemical analysis of differential expression of
p53, p21Waf1 or MDM2 in control (Ctrl)- or doxorubicin (Doxo)-treated breast tumors after 48 h. Tissue morphology and proliferative index were
determined by hematoxylin and eosin (H&E) and Ki-67 staining of the same cases, respectively. A representative case for Non Responder (left) or
Responder (right) breast tumors ex vivo is shown. Original magnification, x200. (B-D) Quantification of p53 (B), p21Waf1 (C) or MDM2 (D) proteins
levels in Ctrl or Doxo-treated Responder versus Non Responder breast tumors at the indicated time intervals. #P = 0.03 *P = 0.01; **P = 0.007
(unpaired t test).
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in organotypic breast tumors
To identify a potential molecular basis of doxorubicin
resistance in ex vivo breast tumors, we next looked at
the expression of 92 apoptotic regulatory genes in or-
ganotypic breast tumors at T0 baseline. Array profiling
studies revealed a global deregulation of p53 pathway
activation in Non Responder versus Responder tumors
(Figure S3A in Additional file 1), potentially affecting
DNA damage-induced cell death, cell cycle transitions,
and tumor metabolic reprogramming (Figure S3B in
Additional file 1). Specifically, supervised analysis of array
profiling data identified BIRC5 (survivin), BIRC3 (cIAP2)
and TNFα as the most deregulated transcripts in Non Re-
sponder tumors under these conditions (Figure S3A in
Additional file 1). Consistent with these findings, wild-
type survivin (Figure S3C in Additional file 1), and its
alternatively spliced variant survivin-ΔEx3 (P = 0.006,
Figure S3D in Additional file 1), were validated by
quantitative PCR as significantly differentially expressed in
Non Responder versus Responder tumors (n = 29). In con-
trast, the survivin splice variant survivin-2B was com-
parably expressed in the two subgroups of organotypic
breast tumors (Figure S3E in Additional file 1). Despite a
trend was observed for differential increased expression
of TNFα (Figure S4A in Additional file 1), and BIRC3(Figure S4B in Additional file 1) in Non Responder com-
pared to Responder tumors, these changes did not reach
statistical significance. Although survivin functions as a
broad apoptosis inhibitor and mitotic regulator in genetic-
ally heterogeneous tumors [29], survivin-ΔEx3 has been
selectively associated with modulation of the DNA da-
mage response, selectively in tumors [26]. Accordingly,
survivin-ΔEx3 was differentially expressed in breast
tumors with high proliferative index, as determined
by Ki-67 immunoreactivity (>15% Ki-67+ cells; Figure 4A,
P = 0.03). Mechanistically, overexpression of survivin-ΔEx3
in MCF-7 cells treated with doxorubicin (Figure S5A in
Additional file 1) prevented loss of cell viability (P = 0.02;
Figure 4B), and significantly decreased the number of
apoptotic cells (P = 0.01; Figure 4C) after doxorubicin
treatment. In control experiments, forced expression of
survivin-ΔEx3 did not affect DNA foci formation in MCF-7
cells, as determined by γH2AX-nuclear staining (Figure
S5B and C in Additional file 1).
Incorporation of survivin-based molecular therapy in
breast cancer treatment
The results above suggest that survivin family proteins
may function as key determinants of doxorubicin-
resistance in organotypic breast tumors. To further test
this possibility, we next used a high-throughput format
Figure 4 Role of survivin family proteins in doxorubicin resistance in breast cancer. (A) Human breast tumors with low (Ki-67 ≤ 15%)
or high (Ki-67 > 15%) proliferative index were analyzed for differential expression of survivin-ΔEx3 by qPCR. *P = 0.03. (B, C) MCF-7 cells were
transfected with survivin-ΔEx3 (SVV-ΔEx3) or control vector (Ctrl), treated with 1 μM doxorubicin or vehicle, and analyzed for cell viability (B) or
apoptosis (C) after 48 h by an 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) or terminal deoxynucleotidyl transferase dUTP
nick-end labeling (TUNEL) assay, respectively. *P = 0.01; **P = 0.002 (unpaired t test).
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cline chemotherapy plus the small-molecule survivin
suppressant, sepantronium bromide (YM155) currently
evaluated in the clinic [30]. The combination of YM155
plus doxorubicin in these settings produced extensive
antitumor synergy against breast cancer MCF-7 cells
(Figure 5), and robust inhibition of cell proliferation
at various concentrations of the two agents tested
(Figure 6A). In contrast, the combination of YM155 withFigure 5 Combination effects of YM155 and cancer chemotherapeuti
YM155 (dose range 0.0004 to 0.100 μmol/L), in combination with either do
range per each agent, 0.004 to 1 μmol/L) as a 7 × 7 matrix of concentratio
and percentage of growth inhibition (right) are shown as a concentration rtaxol, camptothecin (CPT) or etoposide was not syner-
gistic and produced suboptimal antitumor activity against
breast cancer cells (Figure 5). Consistent with these find-
ings, the addition of YM155 significantly enhanced
doxorubin-mediated killing of a panel of genetically het-
erogeneous breast cancer cell types, compared to each
treatment alone (Figure 6B). When analyzed for mecha-
nisms of antitumor activity, the combination of YM155
plus doxorubicin increased the fraction of tumor cells withcs on breast cancer cell viability. MCF-7 cells were treated with
xorubicin (Doxo), taxol, camptothecin (CPT), or etoposide (ETOP, dose
ns in a cell viability assay. The excess over BLISS independence (left)
ange for each drug combination.
Figure 6 Therapeutic targeting of survivin pathway in breast cancer cell types. (A) MCF-7 cells were incubated with the indicated increasing
concentrations of doxorubicin (Doxo) alone or in combination with YM155 and analyzed for cell viability after 48 h. Data are representative of one
experiment out of two independent determinations. (B) The indicated breast cancer cell types were incubated with vehicle (Veh, DMSO), Doxo or
YM155, alone or in combination and analyzed for cell viability by Trypan blue exclusion after 48 h. (C) MCF-7 cells were treated with the various drug
combinations as indicated and analyzed for hypodiploid DNA content (sub-G1), by propidium iodide and flow cytometry. For panels B and C, data are
the mean ± SEM of replicates of a representative experiment out of two independent determinations. (D) MCF-7 cells treated as in B, C were analyzed
by Western blotting. The positions of cleaved products for poly-ADP ribose polymerase (PARP) or caspase-3 are indicated.
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try (Figure 6C), with increased cleavage of canonical apop-
tosis markers, including PARP and caspase-3, by Western
blotting (Figure 6D).
Discussion
In this study, we have shown that fresh, treatment-naïve
organotypic human breast tumors closely recapitulating
the human disease [22] can be stratified into two discrete
subgroups that differ sharply in their response to doxo-
rubicin with respect to proliferative status, p53 func-
tion and modulation of apoptosis. Doxorubicin-insensitive
(that is Non Responder) tumors selectively contained high
levels of survivin family proteins, including the alter-
natively spliced survivin-ΔEx-3 isoform, which was
directly implicated in treatment resistance. Conversely,
high-throughput targeting this pathway with a small-
molecule survivin suppressant currently in the clinic
(YM155) selectively synergized with doxorubicin, and
restored apoptosis in heterogeneous breast cancer
cell types.Despite the advent of molecular therapies [2], and
the improved survival of patients with advanced disease
[31], the emergence of treatment-resistant breast cancer,
in particular to first-line anthracycline-containing chemo-
therapy, remains a formidable challenge [10], with limited
therapeutic options. The organotypic approach described
here [22] identified a functional subset of treatment-naïve
breast tumors with nearly complete insensitivity to doxo-
rubicin, characterized by no significant reduction in cell
proliferation or appearance of apoptosis in response to
treatment. At least in the patient series examined here,
the Non Responder phenotype did not appear to segregate
with other markers of poor outcome in breast cancer,
for instance HER2 overexpression/amplification or p53
mutations. Although analysis of a larger patient cohort
may be required to conclusively address this point,
the high proliferative status constitutively observed in
Non responder breast tumors by Ki-67 staining [32],
has been previously associated with drug-resistant dis-
ease and poor outcome [33].
The mechanisms of primary drug resistance in breast
cancer are still largely elusive [34], but there is evidence
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in particular survivin [29], confers insensitivity to mo-
lecular [35,36] or endocrine [37] therapies, resulting in
shortened overall survival [38]. Here, the increased ex-
pression of survivin and its alternatively spliced survivin-
ΔEx3 variant provided for the single, most significant
deregulation of apoptotic pathways in Non Responder
breast tumors, and recombinant expression of survivin-
ΔEx3 was sufficient, alone, to confer doxorubicin resis-
tance in model breast cancer cell types. It is possible that
deregulation of the survivin pathway in Non Responder
tumors may reflect the defective p53 responses that were
also observed in these patients, as loss of p53-dependent
repression of the survivin promoter [39] has been asso-
ciated with increased survivin gene transcription, inclu-
ding its alternatively spliced variants [40].
Consistent with the data presented here, survivin-
ΔEx3 has been recognized as a bona fide mediator of
cytoprotection, elevating an antiapoptotic threshold in
tumors [41]. However, there is also evidence that this
molecule may function as a sensor of DNA damage,
specifically DSB, and selectively in the transformed cell
population [26]. A mechanistic underpinning of this
response has been proposed, involving isoform-specific
phosphorylation of survivin-ΔEx3 by the checkpoint kin-
ase, Chk2, and time-dependent recruitment of γH2AX, a
marker of unrepaired DNA damage [42], to nuclear foci
[26]. This scenario may be relevant to the data presented
here, as increased expression of survivin-ΔEx3 in Non
Responder tumors may promote early recruitment of
the DNA repair machinery to DSB, and together with
a higher antiapoptotic threshold, limit the anticancer
activity of genotoxic stress, including doxorubicin [26].
Indeed survivin-ΔEx3 overexpression may counter the
preferential killing of highly proliferating tumor cells by
doxorubicin, thus diminishing the efficacy of chemo-
therapy against this potentially susceptible cellular
compartment.
Accordingly, retrospective bioinformatics analyses have
linked high expression of survivin-ΔEx3 to unfavorable
outcome in various patient series [26], further supporting
the more general role of survivin as a poor prognostic
marker in breast cancer [43].
Although there is overwhelming evidence that survivin
is an important therapeutic target in disparate tumors,
including breast cancer [44], the portfolio of survivin
antagonists suitable to target this pathway in the clinic
has remained disappointingly narrow [15]. Currently,
only the small-molecule sepantronium bromide, YM155
[45], proposed to act as a transcriptional suppressant of
the survivin locus, has shown good tolerability and pre-
liminary evidence of activity in early-phase trials [44].
On the other hand, survivin is overexpressed in virtually
every human tumor [15], making it difficult to identifydiscrete patient subset(s) likely to benefit from YM155-
based therapy, and only limited information is available
to rationally guide the incorporation of survivin anta-
gonist(s) in effective combination regimens. The present
study may help bridge this gap, uncovering a synergistic
response between YM155 and doxorubicin that induced
apoptosis in heterogeneous breast cancer cell types.
Consistent with a role of survivin family proteins in
DNA repair mechanisms [26], YM155 triggered a DNA
damage response in tumor cells [46], and potentiated
the antitumor activity of ionizing radiation in non-small
cell lung cancer [47]. Conversely, the combination of
YM155 plus taxol, etoposide or camptothecin was not
synergistic in our high-throughput analysis, and had
minimal anticancer activity in breast cancer cells. This is
reminiscent of other data in the clinic, where the com-
bination of YM155 plus carboplatin/paclitaxel produced
only limited responses in non-small cell lung cancer
patients [48].
Conclusions
In summary, we used fresh cultures of treatment-naïve
organotypic breast tumors that closely mimic the disease
in patients [22] to identify survivin family proteins as
drivers of primary doxorubicin resistance across breast
cancer subgroups. Despite the introduction of YM155 in
the clinic over five years ago [30], the suitability of this
treatment in breast cancer has not been clearly demon-
strated. The results presented here suggest that incorpor-
ation of YM155 in anthracycline-containing chemotherapy
may result in greater clinical activity across heterogeneous
breast cancer subtypes, and potentially overcome constitu-
tive treatment resistance in these patients.
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